Close Menu

NEW YORK – Luminex reported after the close of the market on Monday that its 2019 third quarter revenues were up 9 percent year over year.

For the quarter ended Sept. 30, the molecular diagnostics company reported revenues of $78.7 million compared to $72.4 million in the year-ago quarter, and missed the average Wall Street estimate for revenues of $81.8 million.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sep
30
Sponsored by
LGC SeraCare Life Sciences

Non-invasive prenatal testing (NIPT) continues to expand globally to support maternal-fetal patient care. 

Oct
09
Sponsored by
PerkinElmer

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.